ProbeChem®
Expedite Your Scientific Research

WWW.PROBECHEM.COM

Data Sheet

Global Supplier of Chemical Probes, Inhibitors & Agonists.

Product Name	:	NVL-655
Cat. No.	:	PC-23342
CAS No.	:	2739866-40-9
Molecular Formula	:	$C_{23}H_{22}ClFN_6O$
Molecular Weight	:	452.92
Target	:	Anaplastic Lymphoma Kinase (ALK)
Solubility	:	10 mM in DMSO



Biological Activity

Neladalkib (NVL-655) is a potent, selective and brain-penetrant fourth-generation inhibitor of diverse **ALK-mutant oncoproteins** with IC50 of 0.9 nM and 1.8 nM for WT ALK and ALK G1202R/L1196M mutant respectively.
Neladalkib (NVL-655) potently inhibits cell lines expressing WT ALK fusions with average IC50 < 1.1 nM.
Neladalkib (NVL-655) exhibits an IC50 of 0.3 to 1.6 nM against MGH048-1, MGH064-1, and MGH026-1 cell lines, which were established from TKI-naïve patients with NSCLC harboring EML4–ALK v1, v2, and v3 fusions, respectively, and IC50 of 2 nM against the anaplastic large cell lymphoma cell line Karpas299 harboring the NPM1–ALK fusion.
Neladalkib (NVL-655) potently inhibits the growth of cell lines harboring ALKG1202R fusions (IC50 = 0.1–0.8 nmol/L, average
< 0.3 nM), including three PDCs established after progressive disease on alectinib (MGH953-4 and YU1077) or brigatinib (MGH9037-2).
Neladalkib (NVL-655) is >14-fold more potent than zotizalkib, >100 fold more potent than lorlatinib, and >280-fold more potent
than 1G and 2G ALK TKIs on average.
Neladalkib (NVL-655) inhibits ALK over TRK with 22-fold to >874-fold selectivity.
Neladalkib (NVL-655) demonstrates preliminary proof-of-concept clinical activity in heavily pretreated patients with ALK fusion-positive non-small cell lung cancer, including in patients with brain metastases and single or compound ALK resistance mutations.

References

Lin JJ, et al. ***Cancer Discov***. 2024 Sep 13:OF1-OF20.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com